These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 26124641

  • 1. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H, Shi C, Yan Z, Li H.
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [Abstract] [Full Text] [Related]

  • 2. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC.
    Cancer; 2020 Feb 15; 126(4):894-907. PubMed ID: 31714594
    [Abstract] [Full Text] [Related]

  • 3. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.
    Gynecol Oncol; 2016 Sep 15; 142(3):548-56. PubMed ID: 27426307
    [Abstract] [Full Text] [Related]

  • 4. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.
    Int J Oncol; 2015 Jul 15; 47(1):262-8. PubMed ID: 25975349
    [Abstract] [Full Text] [Related]

  • 5. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.
    Clin Cancer Res; 2011 Feb 15; 17(4):783-91. PubMed ID: 21097693
    [Abstract] [Full Text] [Related]

  • 6. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells.
    Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    Mol Cancer Ther; 2020 Jan 15; 19(1):199-210. PubMed ID: 31534014
    [Abstract] [Full Text] [Related]

  • 7. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R.
    Clin Cancer Res; 2005 Feb 15; 11(4):1572-8. PubMed ID: 15746062
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    Gynecol Oncol; 2016 Aug 15; 142(2):323-31. PubMed ID: 27282964
    [Abstract] [Full Text] [Related]

  • 9. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Aug 15; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 10. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.
    PLoS One; 2018 Aug 15; 13(11):e0207399. PubMed ID: 30444904
    [Abstract] [Full Text] [Related]

  • 11. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    Nat Med; 2016 Feb 15; 22(2):194-201. PubMed ID: 26779812
    [Abstract] [Full Text] [Related]

  • 12. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.
    Gynecol Oncol; 2018 Jun 15; 149(3):575-584. PubMed ID: 29567272
    [Abstract] [Full Text] [Related]

  • 13. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Jun 15; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 14. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.
    Breast Cancer; 2014 Jan 15; 21(1):75-85. PubMed ID: 22454224
    [Abstract] [Full Text] [Related]

  • 15. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 16. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J, Gao Y, Luan X, Li K, Wang J, Dai Y, Kang M, Lu C, Zhang M, Lu CX, Kang Y, Xu C.
    Cancer Chemother Pharmacol; 2022 May 01; 89(5):683-695. PubMed ID: 35419627
    [Abstract] [Full Text] [Related]

  • 17. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.
    Mol Pharm; 2018 Feb 05; 15(2):472-485. PubMed ID: 29283581
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N, Zhang Q, Fang S, Han X, Wang Z.
    Oncotarget; 2017 Feb 07; 8(6):9134-9143. PubMed ID: 27852073
    [Abstract] [Full Text] [Related]

  • 19. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
    Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, Ge Y.
    Cancer Lett; 2014 Jun 28; 348(1-2):20-8. PubMed ID: 24534203
    [Abstract] [Full Text] [Related]

  • 20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.